

REMARKS

Claim 91 has been amended to include a SEQ ID number which was omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**".


The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing for the above-captioned application, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 399632000420. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 5, 2001

By:



Bruce Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125

MARKED-UP VERSION OF AMENDMENTS TO THE CLAIMS

In the Claims

91. (New) An isolated antigenic HLA-A3 binding peptide derived from a HIV-1 protein having the following formula:

Xaa₁Xaa₂Xaa₃Xaa₄Xaa₅Xaa₆Xaa₇Xaa₈Xaa₉Xaa₁₀

wherein Xaa₂ is Leu, Met, Ile, Val, Ser, or Thr, and Xaa₁₀ is Lys or Arg, and said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said decapeptide. (SEQ ID NO. 104)